oalib
Search Results: 1 - 10 of 100 matches for " "
All listed articles are free for downloading (OA Articles)
Page 1 /100
Display every page Item
Bronquiolite obliterante com pneumonia em organiza o e aspergiloma em paciente com linfoma-leucemia de células T  [cached]
JHAYYA TERESA S.,PEREZ DOMINGO B.,LLARGES CELIA MALLART,FERREIRA RIMARCS G.
Jornal de Pneumologia , 2000,
Abstract: Há poucos relatos na literatura médica referentes à associa o de bronquiolite obliterante com pneumonia em organiza o (BOPO) e aspergiloma. Apresenta-se uma associa o de BOPO e aspergiloma pulmonar em uma paciente com linfoma-leucemia de células T do adulto. Sugere-se que os achados deste caso representam uma associa o fortuita e n o a express o de unidade nosológica.
Linfoma de Hodkin en Chile: Experiencia de 15 a?os del Programa Nacional de Cáncer del Adulto
Cabrera C,M Elena; García L,Hernán; Lois V,Vivian; León R,Alvaro; Pe?a N,Karina; Rossle S,Alberto; Cerda A,Berta; Rojas R,Hernán; Meneses C,Pedro; Merino M,Carlos; Aspillaga M,Augusto; Vittini de R,Cecilia; Oliva L,Jacqueline; Hales D,Cecilia; Rosas H,Janet;
Revista médica de Chile , 2007, DOI: 10.4067/S0034-98872007000300009
Abstract: background: hodgkin lymphoma is a highly curable disease. aim: to evaluate the clinical characteristics and the treatment results of hodgkin lymphoma patients of the national cancer program in chile. patients and methods: prospective assessment of 682 patients treated in 18 adult cancer centers. progression free survival (pfs) and overall survival (os) were calculated. median follow up was 127, 95, 87, 72 and 50 months for c-mopp, radiotherapy (rt), c-mopp/abv, novp and abvd, respectively. results: median age was 37 years (15-84). nodular sclerosis and mixed cellularity were equally expressed. advanced stages (iii & iv) were present at diagnosis in 61% of cases. age over 40 was an adverse prognostic factor (p <0.001). the rate of pfs at 5 and 10 years for early stages was 73% and 66% with rt, 80% and 74% with c-mopp+rt, 73% and 71% with c-mopp/abv, 59% and 59% with novp+rt, and 81% with abvd+rt, at 5 years, being significantly lower for novp (p =0.02). the rate of os at 5 and 10 years for advanced stages was 82% and 70% with rt, 82% and 76% with c-mopp+rt, 82% and 80% with c-mopp/abv, 68% and 60% with novp, and 85% with abvd at 5 years, also significantly lower for novp (p =0.04). for advanced stages, the rate of pfs at 5 and 10 years was 49% and 43% with c-mopp, 69% and 62% with c-mopp/abvd or c-mopp/abv, and 71% at 5 years with abvd, significantly lower for c-mopp (p =0.01). the rate of os at 5 and 10 years was 52% and 46% with c-mopp, 70% and 63% with c-mopp/abvd or c-mopp/abv and 76% with abvd at 5 years, significantly lower for c-mopp (p =0.0002). conclusions: age over 40 years was an adverse prognostic factor. c-mopp/abvd, c-mopp/abv and abvd had comparable results and reached a high tumor control and overall survival in both early and advanced stages
Linfoma de Hodkin en Chile: Experiencia de 15 a os del Programa Nacional de Cáncer del Adulto Hodgkin lymphoma in Chile: Experience of the national adult cancer program  [cached]
M Elena Cabrera C,Hernán García L,Vivian Lois V,Alvaro León R
Revista médica de Chile , 2007,
Abstract: Background: Hodgkin lymphoma is a highly curable disease. Aim: To evaluate the clinical characteristics and the treatment results of Hodgkin lymphoma patients of the National Cancer Program in Chile. Patients and methods: Prospective assessment of 682 patients treated in 18 adult cancer centers. Progression free survival (PFS) and overall survival (OS) were calculated. Median follow up was 127, 95, 87, 72 and 50 months for C-MOPP, radiotherapy (RT), C-MOPP/ABV, NOVP and ABVD, respectively. Results: Median age was 37 years (15-84). Nodular sclerosis and mixed cellularity were equally expressed. Advanced stages (III & IV) were present at diagnosis in 61% of cases. Age over 40 was an adverse prognostic factor (p <0.001). The rate of PFS at 5 and 10 years for early stages was 73% and 66% with RT, 80% and 74% with C-MOPP+RT, 73% and 71% with C-MOPP/ABV, 59% and 59% with NOVP+RT, and 81% with ABVD+RT, at 5 years, being significantly lower for NOVP (p =0.02). The rate of OS at 5 and 10 years for advanced stages was 82% and 70% with RT, 82% and 76% with C-MOPP+RT, 82% and 80% with C-MOPP/ABV, 68% and 60% with NOVP, and 85% with ABVD at 5 years, also significantly lower for NOVP (p =0.04). For advanced stages, the rate of PFS at 5 and 10 years was 49% and 43% with C-MOPP, 69% and 62% with C-MOPP/ABVD or C-MOPP/ABV, and 71% at 5 years with ABVD, significantly lower for C-MOPP (p =0.01). The rate of OS at 5 and 10 years was 52% and 46% with C-MOPP, 70% and 63% with C-MOPP/ABVD or C-MOPP/ABV and 76% with ABVD at 5 years, significantly lower for C-MOPP (p =0.0002). Conclusions: Age over 40 years was an adverse prognostic factor. C-MOPP/ABVD, C-MOPP/ABV and ABVD had comparable results and reached a high tumor control and overall survival in both early and advanced stages
Leucemia/linfoma de células T do adulto
Bittencourt, Achiléa L.;Farré, Lourdes;
Anais Brasileiros de Dermatologia , 2008, DOI: 10.1590/S0365-05962008000400011
Abstract: adult t cell leukemia/lymphoma (atl) is an aggressive type of lymphoproliferative disease associated with the human t-cell lymphotropic virus type i (htlv-i) that is characterized by a short survival time and absence of response to chemotherapy. atl is classified into four clinical types: acute, chronic, lymphoma, and smoldering. another clinical form of atl, the primary cutaneous tumoral,with diverse characteristics, has been recently suggested. patients with acute, lymphoma and primary cutaneous tumoral types have a poor prognosis. the diagnostic criteria of atl consist of: positive serology for htlv-i; cytologic or histologic confirmation of cd4+/cd25+ t-cell leukemia/lymphoma; abnormal t lymphocytes in peripheral blood; and confirmation of monoclonal integration of htlv-i proviral dna. there is skin involvement in around 70% of atl cases, which could be primary (smoldering and primary cutaneous tumoral) or secondary. the skin lesions are multiple, erythroderma, papules and plaques being the most common. atl has no characteristic histological pattern, and may present patterns that could superimpose nonspecific peripheral t-cell lymphoma, mycosis fungoides or anaplastic large cell lymphoma. the immunohistochemistry pattern may also be similar to that of other t-cell lymphomas. thus, it is very important that in brazil htlv-i infection be investigated in all mature t-cell leukemias/lymphomas.
Leucemia / linfoma T del adulto: Primer caso en Cuba
Mu?ío Perurena,Jorge E.; Díaz Torres,Héctor M.; Carnot Uria,José; de Castro Arenas,Raúl; Navea Leyva,Leonor; Rodríguez Reyes,Inocente;
Revista Cubana de Medicina , 2003,
Abstract: the case of a female patient with diagnosis of non hodgkin lymphoma of aggressive histology in 1990 was presented .according to the clinical findings and to the results of the complementary tests made, it was suspected the possibility of adult t-cell leukemia/lymphoma (atll) related to human t lymphotropic virus type i (htlv-1) infection, which was confirmed by the results of the virological studies. it was observed a torpid evolutive behavior and therapeutic response. the patient died during the first 4 months of the diagnosis, which corroborated what is published in medical literature on this topic.this is the first case diagnosed in cuba of an adult t-cell leukemia/lymphoma associated with htlv-1.
Linfoma/Leucemia de células T do adulto
Borducchi D.M.M.,Kerbauy J.,Oliveira J.S.R. de
Revista da Associa??o Médica Brasileira , 1999,
Abstract:
Leucemia mieloide aguda del adulto: Resultados del Protocolo Nacional de Drogas Antineoplásica. Hospital del Salvador 1990-1998 Acute myeloid leukemia in the adult: Results of the National Antineoplastic Drug Protocol (Panda) at the Hospital del Salvador, Chile  [cached]
Barbara Puga L,María Elena Cabrera C,María Soledad Undurraga S,Raúl Etcheverry B
Revista médica de Chile , 2000,
Abstract: Background: The incidence of acute myeloid leukemia is 3 cases per 100.000 inhabitants/year and its five years event free survival is 15 to 20%. Since the incorporation of trans retinoic acid, event free survival of M3 acute myeloid leukemia is 80%. Aim: To report the results of acute myeloid leukemia treatment at the Hospital del Salvador, between 1990 and 1998. Patients and methods: The medical records of 117 patients (66 female, mean age 48.2 years), treated between 1990 and 1998 using PANDA protocol, were retrospectively reviewed. Immunophenotyping was done in 69 patients and cytogenetic studies were done in 65. Results: Sixteen percent of patients had M3 acute myeloid leukemia. The most frequent phenotype was the association of DR, CD34 plus a panmyeloid marker. DR and CD34 were negative in seven of nine patients with M3 acute myeloid leukemia. Cariotype was abnormal in 78% of patients. Complete remission was achieved in 65% of cases with a 13% of failures. Early mortality was 21.3% and decreased to 6.1% in the last three years. Infections and coagulation disorders were the main causes of death. Mean survival was 10.5 months. Five years event free survival was 11%. In M3 acute myeloid leukemia, the figure is 50%. Conclusions: Treatment results are less effective than protocols that consider more aggressive chemotherapeutic protocols or bone marrow transplantation. The reduction in early mortality is due to a better management of febrile neutropenia (Rev Méd Chile 2000; 128: 1191-98)
estatinas afectan la viabilidad de líneas celulares de leucemia y linfoma humanas in vitro
Mery Guerrero,Camilo Di Giulio,Juan Bautista De Sanctis
Revista de la Facultad de Medicina , 2010,
Abstract: Se ha propuesto que las estatinas inducen apoptosis sobre células tumorales. Para probar dicha hipótesis, se analizó el efecto de las estatinas atorvastatina, fluvastatina, lovastatina, mevastatina, pravastatina y simvastatina en el rango de concentraciones de 1 pM hasta 100 μM, sobre la viabilidad de las líneas celulares humanas Jurkat E6.1, Jurkat D1.1 (Linfoma T) , Daudi (Linfoma B), U937 (leucemia monocítica) y HL-60 (leucemia promielomonocítica) in vitro en cultivos de 48 horas, analizados por la técnica de hidrolización del compuesto bromuro de 3-(4,5-dimetiltiazol-2-il)-2,5-difenilltetrazolio (MTT). Lovastatina y mevastatina son los más potentes inductores de muerte celular independientemente del tipo celular (Ic 50 entre 12 y 50 μM). Para las otras estatinas se observan diferencias en el Ic50 según la línea celular atorvastatina (38,1 y 48,6 μM Jurkats, 55,3 μM Daudi y 100 μM para las otras líneas), pravastatina (25 μM HL-60, 55,6 y 60,7 μM Jurkats y ≥ 100 μM Daudi y U937), simvastatina (25,1 μM Jurkat D1.1, 50,2 μM Jurkat E6.1, 45,2 μM Daudi y 51,3 μM HL-60, y > 100 μM U937) y para fluvastatina en todos los casos > 100 μM. La disminución de la viabilidad celular se revierte completamente cuando las células son incubadas con 10 μM mevalonato. Se concluye que la lovastatina y mevastatina son las más potentes inductoras de muerte seguida por atorvastatina, pravastatina y simvastatina cuyo efecto depende del tipo de línea celular y la fluvastatina no tiene efectos importantes en la viabilidad de las líneas celulares estudiadas. Statins have been proposed to induce apoptosis of tumor cells. In order to test this hypothesis, the effect of atorvastatin, fluvastatin, lovastatin, mevastatin, pravastatin, simvastatin on cell viability was assessed by in vitro culture for 48 hr, at concentrations ranging from 1 pM to 100 μM on human cell lines Jurkat E6.1, Jurkat D1.1 (T cell lymphoma), Daudi (B cell lymphoma), U937 (monocitic leukemia) and HL-60 (pro mielomonocitic leukemia) and analyzed the oxidation of (3-(4.5-Dimethylthiazol-2-yl)-2.5- diphenyltetrazolium bromide (MTT). Lovastatin and mevastatin are the most potent inductors of cell death independently of the cell type (Ic 50 between 12 and 50 μM). Differences in the Ic50 are observed depending on the cell line: atorvastatina (38.1 and 48.6 μM Jurkats, 55.3 μM Daudi y 100 μM for the others lines), pravastatin (25 μM HL-60, 55.6 y 60.7 μM Jurkats and ≥ 100 μM Daudi and U937), simvastatin (25.1 μM Jurkat D1.1, 50.2 μM Jurkat E6.1, 45.2 μM Daudi and 51,3 μM HL-60, and > 100 μM U937) and for fluvastatin >
Mortalidad del adulto en Chile
Medina L,Ernesto; Kaempffer R,Ana M.;
Revista médica de Chile , 2000, DOI: 10.4067/S0034-98872000001000011
Abstract: background: the study of mortality of human groups is important to judge the health conditions of population. aim: to study the main mortality features among chilean adults. material and methods: information about mortality in chile from the instituto nacional de estadísticas and the world health organization, was analyzed. data was expressed mainly as rates. results: annual mortality risk among chileans is 812 per 100,000 inhabitants and is low compared to the rest of latin america. in the last 30 years it has decreased systematically at a rate of 1% per year in both genders. the risk of mortality caused by cerebrovascular disease, coronary heart disease, hepatic cirrhosis, gastric cancer and tuberculosis has decreased. on the other hand, the risk of mortality caused by diabetes,hypertension and lung, gallbladder, prostate and colorectal cancer has increased. mortality varies from 604 per 100,000 in atacama to 934 per 100,000 in valparaiso. the most factor that influences thiis variation is population aging. mean survival at the start of adulthood is 54 years in men and 61 years in women. at 60 years, the expectancy is 19 and 24 years respectively. mean age of death in chile was 71,5 years in 1998. seventy six percent of deaths occurs in the elderly and 33%, in people of 80 years or more. conclusions: chile is one of the four latin american countries with lower mortality risk. in the last 30 years, the main causes of deaths among adults, with exception of pneumonia, have decreased. therefore health care of the adult is in the correct track (rev méd chile 2000; 128: 1144-49).
Mielopatia transversa em adulto portador de leucemia aguda linfoblástica: relato de caso  [cached]
Brito José Correia de Farias,Nóbrega Paulo Virgolino da,Guedes Filho Gilson Espínola,Santos Franklin José Candido
Arquivos de Neuro-Psiquiatria , 2001,
Abstract: Relatamos um caso de mielopatia transversa aguda em paciente masculino de 31 anos de idade, branco, portador de leucemia aguda linfoblástica, subtipo L3 (LLA-L3). Esta é uma forma grave de leucemia e compromete mais crian as em rela o aos adultos. Menos de 1% dos pacientes leucêmicos apresentam complica es espinais. No paciente em estudo, a sintomatologia instalou-se de modo abrupto e com as seguintes características: dores nas costas, paraplegia crural flácida e perda das fun es sensitivas e vegetativas abaixo do segmento afetado. O diagnóstico etiológico foi estabelecido após a realiza o dos seguintes exames: hemograma, mielograma, análise do líquido cefalorraqueano e ressonancia magnética de coluna dorsal. Foi instituído tratamento específico, que n o interferiu com a evolu o fatal da doen a.
Page 1 /100
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.